Better results and fewer side effects with personalised DBS Therapy
sponsored by Boston Scientific
Author: Boston ScientificPublished: 31 May 2018
Prep: Cook: Serves:
Latest Deep Brain Stimulation devices offer a wide range of programming options to help personalise patient treatment. Looking to improve outcomes, Professor Jens Volkmann challenged the status quo and explored promising options
Pharmacological therapy for Parkinson’s disease is aimed at minimising the motor symptoms of the disease, but the side effects of medication can have a significant impact on quality of life. For many people with Parkinson’s – and their carers – motor symptoms are a major burden that can no longer be controlled by medication alone.
For those patients, Deep Brain Stimulation (DBS) therapy could be considered as a safe and effective surgical option. Until recently, DBS was only considered for people who had been living with Parkinson’s for several years. However, recent studies have shown that the sooner suitable subjects undergo DBS surgery, the more they can benefit. Professor Jens Volkmann, Professor and Chairman of the Department of Neurology at the University of Wurzburg, explains: “In younger patients, stimulation can be adjusted a lot easier because they don’t have to regain but rather maintain physical activity which makes a huge difference in the results.”
Motor symptoms such as tremor, rigidity, freezing, slowness of movement or involuntary movements can have a debilitating effect on daily life and social activities. DBS is one of the most effective therapies in reducing these symptoms, with some people able to reduce their medication by more than half.
Beneficial and safe results through personalised DBS therapy
To improve the outcomes of DBS therapy even further, ongoing studies are examining ways of avoiding potential side effects. Professor Volkmann says: “Our brains are all very individual and so is every course of Parkinson’s disease. As a result, every patient responds to DBS differently.”
Today, there are options to individualise and customise each person’s therapy so they can best benefit from it. Professor Volkmann adds: “With personalised stimulation, we can address the individual requirements of a patient’s brain so they can experience the beneficial results from it and also avoid side effects, such as speech disorder, at the same time.”
Shorter stimulation duration is key to fewer side effects
The latest device advancements on the market offer a very wide range of stimulation settings. Trying to identify the ideal setting options, together with a team, Professor Volkmann went against the status quo and found very interesting results. In particular, the team looked at adjusting the “pulse width”, which is one of the stimulation options.
Professor Volkmann says: “Within one second, approximately 130 electrical pulses are repeated to stimulate a specific area in the brain. With this electrical stimulation, we achieve a beneficial effect in a patient. The duration of each of these pulses is called the pulse width. Regulating the pulse width is comparable to dosing a medication. If the dosage of a drug is too low it will not be effective, if it is too high, the patient experiences side effects. With pulse width it is very similar.”
The study found that patients stimulated at a significantly lower pulse width experienced equally good results with even fewer side effects compared to those stimulated at the standard pulse width. He adds: “The newest devices enabled us to respond to the individual requirements of a patient’s brain in a way that was not possible before. This way, patients can receive an equally beneficial and even safer therapy.
“This is a huge step in the right direction. Researchers are continuously looking to improve DBS therapy and its results. I think it will not take long until we can develop a DBS therapy that is auto-adjusting itself based on the individual requirements of a patient’s brain. Technology is evolving incredibly fast and with research like this we are on the right track of finding ways to offer patients a DBS therapy with the best possible results and the fewest side effects at the same time.”
About Deep Brain Stimulation (DBS) therapy
The DBS procedure includes a modest medical device, which sends signals to the brain. The signals help control the motor functions that are affected by movement disorder symptoms such as tremor, slowness and rigidity. The physician will place one or two insulated wires called leads in the brain. The leads are then connected to the stimulator (similar to a pacemaker), which is typically placed under the skin in the chest. The device produces mild electrical impulses that stimulate a specific region of the brain. This may help regulate signalling in the brain, resulting in improvement of symptoms. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on Deep Brain Stimulation and Parkinson’s, please visit the EPDA website or the Boston Scientific website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”